Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06967961 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

Study acronym: DP-PAN-CANCER
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Jul 1, 2029 to Jul 23, 2029
    • Start date changed from estimate of Jun 30, 2025 to Jul 23, 2025
    • Site details revised
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Interventions: For each patient included, the sample described below will be collected: (Other) to For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes: (Other)
    • Secondary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria shortened, about 3 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Claudius Regaud
76 trials monitored
See 4 trials at risk
Prostate Cancer
2,546 trials monitored
See 172 trials at risk
Melanoma
1,092 trials monitored
See 60 trials at risk
Bladder Cancer
1,055 trials monitored
See 74 trials at risk
and 4 more diseases
A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis. Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer. 450 patients will be enrolled in total.
Trial Details
NCT Number NCT06967961
Lead Sponsor Institut Claudius Regaud
Conditions
(from sponsor)		 Urothelial Carcinoma, Renal Cancer, Prostate Adenocarcinoma, Adenocarcinoma of Endometrium, Cutaneous Melanoma, Soft Tissue Sarcoma (STS), Nonseminomatous Germ Cell Tumor, Seminomatous Germ Cell Tumor +2 more
Related terms Carcinoma, Transitional Cell, Kidney Neoplasms, Melanoma, Neoplasms, Nonseminomatous germ cell tumor, Sarcoma, Uterine Cervical Neoplasms
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov